exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088740 RNA Name: hsa-miR-4709-3p RNA Type: miRNA Chromosome: chr14 Starnd: - Coordinate: Start Site(bp): 74480135 End Site(bp): 74480157 External Links: hsa-miR-4709-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand BCORL1 chrX 129981107 130058083 + COQ8A chr1 226897536 226987545 + DNAJB6 chr7 157335381 157417439 + LAMC1 chr1 183023420 183145592 + PURA chr5 140107777 140125619 + TMEM167A chr5 83052846 83077863 - BIK chr22 43110750 43129712 + CLSTN3 chr12 7129698 7158945 + DHX16 chr6 30653119 30673006 - EMC4 chr15 34225013 34230156 + ETV3 chr1 157121191 157138474 - GATM chr15 45361124 45402327 - MED1 chr17 39404285 39451272 - MED28 chr4 17614641 17634105 + MSH3 chr5 80654652 80876815 + MTRNR2L12 chr3 96617188 96618236 - NDUFA4 chr7 10931943 10940153 - NPC2 chr14 74476192 74494177 - PLBD1 chr12 14503661 14567883 - PLEKHA5 chr12 19129752 19376400 + RACK1 chr5 181236897 181248096 - RBM15B chr3 51391285 51397908 + SLC50A1 chr1 155135344 155138857 + TPRG1L chr1 3625015 3630127 + WNK1 chr12 752579 911452 + miRNA targets: NA circRNA targets: NA lncRNA targets: NA Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.